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Background/Aims: Despite controversy regarding the benefits of immunosup-
pressive therapy in immunoglobulin A nephropathy (IgAN), clinical outcomes 
may vary depending on the patient’s responsiveness to this therapy. This study 
evaluated long-term kidney outcomes according to the extent of proteinuria re-
duction after immunosuppression in IgAN patients. 
Methods: Among 927 patients with biopsy-proven IgAN, 127 patients underwent 
immunosuppression. Time-averaged urine protein-creatinine ratio before and 
within 1 year after start of immunosuppression were calculated, and responsive-
ness to immunosuppression was assessed as the reduction of proteinuria between 
the two periods. Patients were classified into tertiles according to the extent of 
proteinuria reduction. We compared the slopes of estimated glomerular filtration 
rate (eGFR) decline using a linear mixed model, and estimated hazard ratios (HRs) 
for disease progression (defined as development of a ≥ 30% decline in eGFR or 
end-stage renal disease) using a Cox proportional hazard model.
Results: Median extent of proteinuria reduction was –2.1, –0.9, and –0.2 g/gCr in 
the first, second, and third tertiles, respectively. There were concomitant chang-
es in the slopes of annual eGFR decline: –2.03, –2.44, and –4.62 mL/min/1.73 m2 
among the first, second, and third tertiles, respectively. In multivariable Cox anal-
ysis, the HRs (95% confidence intervals) for disease progression were 0.30 (0.12 to 
0.74) in the first tertile and 0.70 (0.34 to 1.45) in the second tertile compared with 
the thirdtertile. 
Conclusions: This study showed that greater proteinuria reduction after immu-
nosuppression was associated with a lower risk of disease progression in patients 
with IgAN, suggesting that responsiveness to immunosuppression may be an im-
portant determinant of kidney outcomes. 
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INTRODUCTION
Immunoglobulin A nephropathy (IgAN) is the most 
common primary glomerulonephritis worldwide, and 
the prevalence of IgAN is higher in East Asians than in 
other ethnicities [1,2]. It is not a totally benign disease, 
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because 20% to 40% of patients progress to end-stage re-
nal disease (ESRD) within 20 years after diagnosis [3,4]. 
Therefore, timely and proper treatment is required to 
delay the progression of IgAN. 
Multiple factors are involved in the development of 
IgAN, but a key step in pathogenesis is the formation 
of immune complexes by binding of autoantibodies to 
galactose-deficient IgA1 [5]. This immunologic mecha-
nism has provided the rationale for immunosuppres-
sive therapy in the management of IgAN. In fact, several 
randomized controlled trials have published findings 
suggesting that corticosteroid treatment reduces pro-
teinuria and improves kidney survival in patients with 
IgAN [6-8]. Based on these results, the Kidney Disease: 
Improving Global Outcome (KDIGO) clinical guidelines 
published in 2012 included indications for corticoste-
roid use as a therapeutic option in IgAN. However, evi-
dence level for this suggestion is low, and the first line 
therapy is still supportive care involving control of blood 
pressure and proteinuria with renin-angiotensin-aldo-
sterone system (RAAS) blockers. Immunosuppressive 
therapy can be considered in patients with persistently 
elevated urinary protein excretion (≥ 1 g/day) after 3 to 
6 months of maximal supportive care [9]. Nevertheless, 
the use of immunosuppression is not widely favored be-
cause not all patients show consistent responsiveness to 
corticosteroids and there are many concerns regarding 
the serious adverse effects of immunosuppression [10]. 
Moreover, a recent German study failed to demonstrate 
superiority of immunosuppressive treatment over in-
tensive supportive care in IgAN patients with persistent 
proteinuria [11]. For this reason, the panels from the 
KDIGO controversies conference in 2018 do not strong-
ly support use of immunosuppression in patients with 
IgAN [12].
Despite such controversy, immunosuppression is 
still a therapeutic option in real-world clinical practice 
and clinical outcomes may vary depending on patients’ 
responsiveness to this therapy. Several studies have in-
vestigated factors associated with responsiveness to 
immunosuppressive therapy and shown that immuno-
suppressive drugs can be effective, particularly in the 
presence of existence of endocapillary proliferation, pre-
served renal function, and a higher amount of protein-
uria [13,14]. Among these, proteinuria has long been rec-
ognized as the strongest risk factor for the progression 
of IgAN [15-18]. There are various patterns of proteinuria 
response to immunosuppression. Some patients show 
sustained remission, while others experience a rebound 
increase in proteinuria after discontinuation of immu-
nosuppressive drugs. However, few studies have exam-
ined the relationship between the degree of proteinuria 
reduction after immunosuppressive therapy and long-
term kidney outcomes. Therefore, in this retrospective, 
observational study, we used proteinuria reduction as 
a surrogate marker for responsiveness to immunosup-
pressive therapy and investigated the progression of kid-




A flow diagram of the selection of patients is presented 
in Fig. 1. Among 927 patients with biopsy-proven IgAN 
at Yonsei University Severance Hospital and National 
Health Insurance Services Ilsan Hospital between No-
vember 2005 and November 2017, a total of 174 patients 
were considered eligible for the study after excluding 
those with secondary conditions associated with IgAN 
(n = 38) and those not treated with immunosuppression 
(n = 715). Among the patients, those with the following 
conditions were excluded: age at biopsy < 18 years (n = 2); 
started dialysis before biopsy (n = 13); baseline estimated 
glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 
(n = 8); started immunosuppression before biopsy (n = 
8); immunosuppression duration < 30 days (n = 5). We 
further excluded patients with less than two visits after 
biopsy, those with a follow-up duration of less than 3 
months (n = 6), and those with less than two eGFR and 
proteinuria measurements either before or after the 
start of immunosuppressive therapy (n = 5). Two pa-
tients with a T2 lesion were excluded since they also had 
eGFR less than 30 mL/min/1.73 m2 at baseline. There-
fore, 127 patients were included in the final analysis. Pa-
tients were classified into tertiles according to the extent 
of time-averaged proteinuria (TAP) reduction between 
before and within 1 year from the start of immunosup-
pression (Ter1, first tertile; Ter2, second tertile; Ter3, 
third tertile).
The study was conducted in accordance with the Dec-
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laration of Helsinki and approved by the Institutional 
Review Board of Yonsei University Health System Clini-
cal Trial Center (IRB no. 4-2019-0548). Because the study 
was retrospective and patients were de-identified, the 
need for written consent from the patients was waived.
Data collection
Baseline demographic and clinical data including age, 
sex, anthropometric measurements, comorbidities, 
medication history, and blood pressure were collected 
at the time of biopsy and at the start of immunosuppres-
sive therapy. Laboratory parameters such as blood urea 
nitrogen, serum creatinine, hemoglobin, total protein, 
serum albumin, high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C), 
triglycerides, serum electrolytes, spot urine protein, and 
urine creatinine were measured. Serum creatinine con-
centration was measured by the isotope dilution mass 
spectroscopy traceable kinetic Jaffe assay. The eGFR was 
calculated using the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation [19]. During the 
follow-up period, proteinuria was assessed using the 
spot urine protein-to-creatinine ratio (UPCR) because 
24 hour urine protein quantification was not feasible 
at every visit. Pathologic findings were presented using 
the Oxford classification criteria [13,20]. All renal biopsy 
specimens were reassessed by one pathologist blind-
ed to the patients’ clinical data. Because this was not a 
randomized controlled study, there was no pre-set regi-
men, dosage, or duration of immunosuppression. How-
ever, we generally followed the glucocorticoid protocol 
suggested by Pozzi et al. [6] or Manno et al. [7] during the 
initial 6 months. Additional immunosuppression with 
other drugs was performed at the physician’s discretion 
and based on disease status. In this study, we used TAP, 
because proteinuria at a single time-point cannot reflect 
overall proteinuria status. TAP was calculated as the 
weighted mean of UPCR measurements, with weights 
representing time elapsed since the previous measure-
ment [10]. Pre- and post-immunosuppression (IS) TAPs 
were determined using all UPCR measurements within 
12 months before and after the start of immunosuppres-
sion, respectively. Responsiveness to immunosuppres-
sion was represented as the reduction in TAP.
Study outcomes
We hypothesized that kidney function decline would be 
slower over time in patients with greater proteinuria re-
Figure 1. Flow diagram of the study. IgAN, immunoglobulin A nephropathy; eGFR, estimated glomerular filtration rate. 
aSecondary conditions included infection-associated glomerulonephritis and combined autoimmune disease such as He-
noch-Schonlein purpura, systemic lupus nephritis, Sjogren’s syndrome and rheumatoid arthritis, bPatients were categorized 
into tertiles according to the extent of time-averaged proteinuria reduction after immunosuppression.
Total of 927 patients who pathologically diagnosed with lgAN
between November 2005 to November 2017
Exclusion (n = 800)
1) Secondary conditions associated with lgANa (n = 38)
2) No immunosuppression (n = 715)
3) Age at biopsy < 18 years (n = 2)
4) Start dialysis before biopsy (n = 13)
5) Baseline eGFR < 30 mL/min/1.73 m2 (n = 8)
6) Immunosuppression before biopsy (n = 8)
7) Immunosuppression duration < 30 days (n = 5)
8) Less than 2 visits after biopsy or follow-up duration < 3 months (n = 6)
9) Less than 2 measurement for eGFR and proteinuria before/after start of immunosuppressive therapy (n = 5)
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duction. Our primary outcome of interest was the slope 
of eGFR decline after the start of immunosuppression. 
Secondary outcome was disease progression, defined 
as development of a ≥ 30% decline in eGFR or incident 
ESRD [21]. To avoid the possibility of transient eGFR re-
duction being classified as disease progression, at least 
two consecutive measurements of a ≥ 30% decline in 
eGFR were ascertained. The first of these consecutive 
measurements was retrospectively designated as the 
study endpoint. ESRD was defined as initiation of dialy-
sis or kidney transplantation.
Statistical analysis
Continuous variables are expressed as means and 
standard deviations and categorical variables as abso-
lute numbers with percentages. Comparisons between 
groups were performed using Student’s t test or anal-
ysis of variance for continuous variables and the chi-
square test or Fisher’s exact test for categorical variables. 
The Shapiro-Wilk test was performed to determine 
the normality of the distribution of the parameters. If 
the resulting data did not show a normal distribution, 
medians and interquartile ranges were reported; the 
Mann-Whitney U test or Kruskal-Wallis test was then 
used to compare groups. We computed the slope of 
eGFR decline in mL/min/1.73 m2 per year by applying 
a linear mixed-effect model and a sandwich estimator 
of variance to account for correlation within the same 
subject. Following terms were included in the linear 
mixed-effect model: age at start of immunosuppression, 
sex, time from biopsy to start of immunosuppression, 
baseline eGFR, pre-IS TAP, time-averaged SBP, serum 
albumin, and presence of endocapillary hypercellulari-
ty. We assumed that patients with proteinuria reduction 
would continue to show improvement in proteinuria 
after completion of immunosuppressive therapy. Most 
immunosuppressive therapy was completed within 12 
months. Thus, we performed linear mixed-effect anal-
ysis with a turning point at 1 year after the start of im-
munosuppression. Cox proportional hazard model was 
constructed to determine if there was an independent 
association between TAP reduction and disease pro-
gression. The model was adjusted for multiple variables 
that showed statistical significance (p < 0.05) in univari-
ate analysis or had clinical significance in previous stud-
ies. Model 1 was the crude model without adjustment. 
Model 2 was adjusted for age at the start of immuno-
suppression, sex, time from biopsy to start of immuno-
suppressive therapy, and baseline eGFR. Model 3 addi-
tionally included pre-IS TAP and time-averaged SBP. 
Finally, Model 4 was created after further adjustment for 
serum albumin, the presence of endocapillary hypercel-
lularity, and use of renin-angiotensin system blockers 
at start of immunosuppressive therapy. All results were 
expressed as hazard ratios (HRs) and 95% confidence in-
tervals (CIs). Adjusted cumulative renal survival curves 
were plotted after the same adjustments specified for 
the Cox models. Survival time was defined as the time 
interval between the time of starting immunosuppres-
sion and the onset of the endpoint or last follow-up, and 
follow-up loss was censored. Restricted cubic splines 
were used to determine the association between the de-
gree of proteinuria reduction as a continuous variable 
and the H) for disease progression. For all analyses, a p 
value of less than 0.05 was considered statistically sig-
nificant. All statistical analyses were performed using 




Decrements in TAP in each tertile group are shown in 
Supplementary Fig. 1; Ter1 showed the greatest protein-
uria reduction. Baseline characteristics of the patients at 
the time of kidney biopsy are described in Supplemen-
tary Table 1. Median proteinuria was 1.8 g/gCr (range, 
1.2 to 3.3), median eGFR was 79.3 mL/min/1.73 m2 (range, 
61.2 to 103.3), and mean age was 39.6 ± 11.3 years. Seventy-
nine patients (62.2%) were female and 104 (81.9%) pa-
tients had a history of hypertension. Baseline protein-
uria level was significantly higher in Ter1 than in the 
other two groups. In addition, patients in this group had 
a higher cholesterol level and lower albumin level than 
those in the other two groups. There were no significant 
differences in kidney function, blood pressure, kidney 
function, or proportion of Oxford-MEST-C compo-
nents among tertile groups. At the start of immunosup-
pression, median proteinuria was 2.1 g/gCr (range, 1.4 to 
3.5), and median pre-IS and post-IS TAPs were 1.9 g/gCr 
(range, 1.4 to 3.1) and 1.1 g/gCr (range, 0.6 to 1.6), respec-
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tively (Table 1). Median reduction in TAP was –2.1 g/gCr 
(range, –3.7 to –1.5), –0.9 g/gCr (range, –1.0 to –0.7), and 
–0.2 g/gCr (range, –0.4 to 0.5), in Ter1, Ter2, and Ter3, 
respectively. Baseline eGFR at the initiation of immu-
nosuppression was significantly lower in Ter3 than in 
the other two groups. In addition, the time elapsed from 
biopsy to the initiation of immunosuppressive therapy 
was significantly longer in Ter3 than Ter1 and Ter2. 
Immunosuppression medications included glucocor-
ticoids, cyclophosphamide, mycophenolate, and calci-
neurin inhibitors. All patients received corticosteroids 
as first line immunosuppression agents. There were no 
significant differences in the use and cumulative dose 
of immunosuppressive drugs or duration of treatment 
among tertiles.
Changes in eGFR decline rates according to pro-
teinuria reduction
During a mean follow-up of 5.1 years, the overall eGFR 
decline slope of all patients was –2.97 mL/min/1.73 m2/
year (range, –3.99 to –1.95) (Table 2). There were signifi-
cant differences in kidney function decline rates across 
the three tertile groups with corresponding slopes 
of annual eGFR decline of -2.03 mL/min/1.73 m2/year 
(range, –2.95 to –1.11), –2.44 mL/min/1.73 m2/year (range, 
–4.71, –0.17), and –4.62 mL/min/1.73 m2/year (range, –6.52, 
–2.72) for Ter1, Ter2, and Ter3, respectively. Predicted 
eGFR was derived from a piecewise linear mixed-effect 
model, and slower eGFR decline was noted in patients 
with higher TAP reduction; these differences in predict-
ed eGFR persisted over time after completion of immu-
nosuppressive therapy (Fig. 2).
Proteinuria reduction and disease progression
To compare risk of disease progression among ter-
tile groups, a multivariable-adjusted Cox proportional 
hazard model was constructed. During the follow-up 
period, disease progression occurred in 14 (32.6%), 14 
(33.3%), and 25 (59.5%) patients in Ter1, Ter2, and Ter3, 
respectively. Corresponding incidence rates were 75.0, 
91.8, and 143.1 per 1,000 person-years for the respective 
tertile groups. In multivariable Cox proportional hazard 
analysis, the largest reduction in proteinuria was associ-
ated with a lower risk of disease progression. HRs (95% 
CI) for Ter1 and Ter2 compared to Ter3 were 0.33 (range, 
0.14 to 0.79) and 0.75 (range, 0.36 to 1.54), respectively 
(Table 3). Adjusted survival curves showed that time to 
development of disease progression was significantly 
longer in patients with greater TAP reduction than in 
those with the lowest TAP reduction (Fig. 3). Restricted 
cubic spline curve also showed a non-linear relationship 
between the extent of proteinuria reduction and the risk 
for kidney disease progression (Fig. 4). This association 
was more pronounced in patients with proteinuria < 3.0 
g/gCr, but it did not reach statistical significance (Sup-
plementary Table 2). 
Changes in proteinuria after completion of immu-
nosuppression
Finally, we wondered if proteinuria levels may change 
after completion of immunosuppression. To investigate 
this, we first identified relapse of IgAN, defined as oc-
currence of proteinuria higher than 1 g/gCr on two or 
more consecutive tests within 2 years after completion 
of immunosuppression. There were 2 (4.65%), 1 (2.38%), 
and 5 (11.9%) relapses in Ter1, Ter2, and Ter3, respec-
tively. There were fewer relapses in Ter1 than in Ter3. 
Additionally, we conducted extended follow-up assess-
ment of changes in TAP after year 1 (Supplementary 
Fig. 2). In Ter1, TAP level decreased further at year 2 and 
then slightly increased thereafter. In contrast, there was 
a greater rebound increase in TAP in Ter2 from year 
2, and Ter2 had a consistently high TAP level of > 1.0 
g/gCr. This reverse pattern in TAP level between Ter1 
and Ter2 was maintained during the remaining obser-
vation period. In Ter3, TAP level did not decrease and 
increased further in year 6. 
DISCUSSION
In this study, we sought to evaluate long-term kidney 
outcomes according to the extent of proteinuria reduc-
tion after immunosuppressive therapy in patients with 
IgAN. First, we found that the rate of eGFR decline was 
significantly slower in patients with the greatest pro-
teinuria reduction after immunosuppression. Second, 
when comparing eGFR by dividing the follow-up pe-
riod into 1-year intervals, this slower eGFR decline in 
the group with greater proteinuria reduction persisted 
until 7 years after the start of immunosuppressive ther-
apy. Last, the risk of disease progression was lower in 
1174 www.kjim.org https://doi.org/10.3904/kjim.2020.240
The Korean Journal of Internal Medicine Vol. 36, No. 5, September 2021




Tertiles of proteinuria reduction after  
immunosuppressive therapy p value
Ter1 (n = 43) Ter2 (n = 42) Ter3 (n = 42)
Demographic data
Age, yr 41.2 ± 11.4 39.0 ± 9.8 40.7 ± 11.0 43.8 ± 13.0  0.150
Proteinuria, g/gCr 2.1 (1.4–3.5) 3.7 (2.6–5.2) 1.5 (1.3–2.0) 2.0 (1.2–2.8) < 0.001
Pre-IS TAP, g/gCr 1.9 (1.4–3.1) 3.3 (2.7–4.9) 1.5 (1.3–1.9) 1.5 (1.0–2.1) < 0.001
Post-IS TAP, g/gCr 1.1 (0.6–1.6) 1.2 (0.7–1.6) 0.7 (0.4–0.9) 1.6 (0.9–2.3) < 0.001
Reduction of proteinuria, g/gCr –0.9 (–1.8 to –0.4) –2.1 (–3.7 to –1.5) –0.9 (–1.0 to –0.7) –0.2 (–0.4 to 0.5)
SBP, mmHg 122.9 ± 1 3.8 122.4 ± 16.9 121.9 ± 11.2 124.4 ± 12.5  0.710
DBP, mmHg 77.0 ± 9.1 76.0 ± 9.3 76.9 ± 8.4 78.2 ± 9.5  0.560
Laboratory parameter
BUN, mg/dL 16.8 (13.5–22.1) 16.2 (12.9–20.1) 17.1 (14.4–21.0) 16.9 (15.1–24.3)  0.120
Creatinine, mg/dL 1.1 (0.8–1.4) 1.0 (0.7–1.3) 1.0 (0.8–1.5) 1.3 (0.9–1.6)  0.009
eGFR, mL/min/1.73 m2 70.2 (51.6–100.3) 80.6 (64.7–102.1) 73.2 (52.5–93.1) 59.1 (43.6–85.2)  0.018
Hemoglobin, g/dL 12.6 ± 1.8 12.4 ± 1.6 12.9 ± 1.8 12.6 ± 2.0  0.410
Calcium, mg/dL 8.9 (8.6–9.1) 8.7 (8.5–9.0) 8.9 (8.8–9.2) 8.9 (8.7–9.1)  0.023
Inorganic phosphorus, mg/dL 3.7 ± 0.5 3.8 ± 0 .5 3.6 ± 0.4 3.8 ± 0.6  0.400
Uric acid, mg/dL 6.0 (4.9–7.4) 5.6 (4.6–7.1) 6.3 (5.2–7.1) 6.5 (5.5–7.8)  0.080
Total protein, g/dL 6.4 (6.1–6.8) 6.2 (5.5–6.5) 6.7 (6.3–6.9) 6.5 (6.2–6.8)  0.003
Albumin, g/dL 3.8 (3.4–4.0) 3.5 (3.2–3.8) 4.0 (3.7–4.1) 3.8 (3.4–4.0) < 0.001
Total cholesterol, mg/dL 194.0 (173.0–226.0) 209.0 (181.0–249.0) 186.5 (163.0–207.0) 194.5 (173.0–237.0)  0.017
HDL-C, mg/dL 49.0 (40.0–61.0) 49.5 (41.0–63.0) 44.0 (38.5–53.5) 51.0 (45.0–62.5)  0.220
LDL-C, mg/dL 111.0 (91.0–127.0) 118.0 (83.0–164.0) 108.5 (93.0–127.0) 111.0 (91.0–118.0)  0.600
Triglyceride, mg/dL 123.0 (91.0–201.0) 161.0 (96.0–220.0) 123.0 (90.0–193.0) 112.0 (76.0–172.0)  0.140
Na, mmol/L 140.7 ± 1.8 140.5 ± 1.9 140.8 ± 1.7 140.6 ± 1.8  0.710
K, mmol/L 4.5 ± 0.4 4.5 ± 0.3 4.4 ± 0.4 4.6 ± 0.5  0.048
Cl, mmol/L 104.4 ± 2.4 104.8 ± 2.4 104.0 ± 2.5 104.5 ± 2.5  0.400
tCO2, mmol/L 25.1 ± 2.3 24.6 ± 2.5 25.4 ± 2.3 25.2 ± 2.2  0.280
Medication history
ACE inhibitor 4 (3.1) 0 2 (4.8) 2 (4.8)  0.350
ARB 91 (71.7) 30 (69.8) 33 (78.6) 28 (66.7)  0.450
Spironolactone 4 (3.1) 2 (4.7) 2 (4.8) 0  0.540
Statin 35 (27.6) 15 (34.9) 11 (26.2) 9 (21.4)  0.370
Biopsy findings
M1 46 (36.2) 14 (32.6) 11 (26.2) 21 (50.0) 0.063
E1 50 (39.4) 17 (39.5) 21 (50.0) 12 (28.6) 0.130
S1 109 (85.8) 39 (90.7) 33 (78.6) 37 (88.1) 0.240
T1 22 (17.3) 7 (16.3) 9 (21.4) 6 (14.3)  0.670
C1 34 (26.8) 8 (18.6) 16 (38.1) 10 (23.8) 0.280
C2 3 (2.4) 2 (4.7) 0 1 (2.4)
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patients with the greatest proteinuria reduction. These 
findings suggest that proteinuria reduction after immu-
nosuppression can be a surrogate marker for respon-
siveness to immunosuppression and a useful predictor 
of long-term outcomes in patients with IgAN.
Proteinuria is a sign of kidney damage and a well-
known indicator of severity and prognosis in various 
renal diseases [22-25]. In IgAN, proteinuria is the stron-
gest prognostic factor for adverse kidney outcomes, and 




Tertiles of proteinuria reduction after  
immunosuppressive therapy p value
Ter1 (n = 43) Ter2 (n = 42) Ter3 (n = 42)
Immunosuppressants
Number of patients
Glucocorticoid 127 (100.0) 43 (100.0) 42 (100.0) 42 (100.0)
Cyclophosphamide 2 (1.6) 1 (2.3) 0 1 (2.4)  1.000
Mycophenolate 6 (4.7) 2 (4.7) 1 (2.4) 3 (7.1)  0.700
Cyclosporine 27 (21.3) 12 (27.9) 4 (9.5) 11 (26.2)  0.074
Total cumulative dose, g
Glucocorticoid 7.8 (5.6–12.6) 8.3 (6.5–13.1) 7.5 (5.0–12.6) 7.7 (5.3–10.6) 0.420
Cyclophosphamide 9.0 (5.5–12.6) 12.60 None 5.45
Mycophenolate 95.6 (87.0–149.4) 140.8 (81.5–200.0) 92.5a 98.8 (97.8–99.8) 0.860
Cyclosporine 55.9 (25.1–85.9) 55.9 (37.8–87.0) 69.5 (43.5–74.4) 52.9 (11.1–82.8) 0.710
Duration of  
immunosuppression, mon
9.0 (6.6–16.0) 9.7 (7.7–17.6) 8.9 (6.5–10.4) 9.6 (6.2–20.2)  0.280
Time from biopsy to start of 
immunosuppression, mon
1.4 (0.5–18.0) 0.6 (0.5–1.7) 1.2 (0.5–9.4) 15.7 (6.3–56.2) < 0.001
Values are presented as mean±standard deviation, median (interquartile range), or number (%).
IgA, immunoglobulin A; Ter1, first tertile; Ter2, second tertile; Ter3, third tertile; pre-IS TAP, time-averaged proteinuria be-
fore the start of immunosuppressive therapy; post-IS TAP, time-averaged proteinuria within 1 year from the start of immuno-
suppressive therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; eGFR, estimated 
glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ACE, 
angiotensin converting enzyme; ARB, angiotensin receptor blocker.
aOnly one patient was treated with mycophenolate at a mean dose of 92.5 g.
Table 1. Continued
Table 2. Post-treatment slopes of eGFR and comparison of TAP before and after immunosuppressive therapy
Variable No. of cases
Post-treatment slope 
 (95% CI)a
TAP before 1 year from treat-
ment initiation (IQR)
TAP within 1 year from treat-
ment initiation (IQR)
p valueb
Overall 127 –2.97 (–3.99 to –1.95) 1.9 (1.4–3.1) 1.1 (0.6–1.6) < 0.001
Ter1 43 –2.03 (–2.95 to –1.11) 3.3 (2.7–4.9) 1.2 (0.7–1.6) < 0.001
Ter2 42 –2.44 (–4.71 to –0.17) 1.5 (1.3–1.9) 0.7 (0.4–0.9) < 0.001
Ter3 42 –4.62 (–6.52 to –2.72) 1.5 (1.0–2.1) 1.6 (0.9–2.3) 0.975
eGFR, estimated glomerular filtration rate; TAP, time-averaged proteinuria; CI, confidence interval; IQR, interquartile range; 
Ter1, first tertile; Ter2, second tertile; Ter3, third tertile.
aThe slope of eGFR was derived 12 months after the start of immunosuppressive therapy. Adjusted for age at start of immuno-
suppression, sex, time from biopsy to start of immunosuppressive therapy, baseline eGFR, TAP before the start of immuno-
suppressive therapy, time-averaged systolic blood pressure, serum albumin, and presence of endocapillary hypercellularity.
bA p value was derived from a Wilcoxon signed rank test.
1176 www.kjim.org https://doi.org/10.3904/kjim.2020.240
The Korean Journal of Internal Medicine Vol. 36, No. 5, September 2021
gested to delay disease progression [9,26,27]. Consistent 
with this, our findings highlight the importance of pro-
teinuria reduction as a surrogate marker of responsive-
ness to immunosuppression. Several other indicators of 
steroid responsiveness have been proposed, but findings 
have been inconsistent. For example, an earlier study by 
the Working Group of the International IgA Nephrop-
athy Network and the Renal Pathology Society showed 
that the presence of endocapillary hypercellularity im-
plies a good response to corticosteroids [13]. However, 
endocapillary hypercellularity has not been validated as 
a discriminator for treatment response by other cohort 
studies [28-30]. Nevertheless, from a practical viewpoint, 
repeated kidney biopsy is not widely performed and it is 
difficult to determine a treatment response from biop-
sy findings. In contrast, measurement of proteinuria is 
non-invasive and easily performed in clinical practice. 
Thus, serial monitoring of changes in proteinuria can 
be implemented to evaluate responsiveness to immu-
nosuppression. We further showed that the extent of 
proteinuria reduction correlated well with the slopes of 
eGFR decline and was a good predictor of future adverse 
kidney outcomes, suggesting that proteinuria reduction 
is a useful marker of disease progression. Based on our 
results, we strongly support the recent suggestion by 
Thompson et al. [31], that proteinuria reduction is a rea-
sonable endpoint to evaluate the effect of treatment in 
future clinical interventional trials.
It should be noted that patients in Ter1 showed slow-
er disease progression than those in Ter2 despite the 
lower achieved proteinuria level in Ter2. To determine 
why this might be the case, we performed an extended 
follow-up assessment of changes in proteinuria after the 
completion of immunosuppression. Interestingly, pro-
teinuria was further decreased in Ter1 at year 2, whereas 
there was a rebound increase in proteinuria in Ter2 at 
year 2. During the remaining observation period, pa-
tients in Ter2 had a higher proteinuria level (> 1.0 g/gCr) 
than patients in Ter1. Not surprisingly, persistently el-
evated proteinuria > 1.0 g/day is a poor prognostic fac-
Figure 2. Changes in predicted estimated glomerular fil-
tration rate (eGFR) using a piecewise linear mixed model. 
Patients were categorized into tertiles according to the ex-
tent of time-averaged proteinuria reduction after immuno-
suppression. The linear mixed model was used to derive the 
predicted eGFR after adjusting for age at start of treatment, 
sex, time from biopsy to start of immunosuppressive ther-
apy, baseline eGFR, time-averaged proteinuria before the 
start of immunosuppressive therapy, time-averaged systolic 
blood pressure, serum albumin, and presence of endocapil-
lary hypercellularity. Markers and capped spikes represent 
means and 95% confidence intervals. Ter1, first tertile; Ter2, 
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Table 3. Cox proportional hazard model of disease progressiona according to reduction of proteinuria after immunosuppres-
sive therapy
Variable 
Model 1 Model 2 Model 3 Model 4
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Ter1 0.51 (0.26–0.98) 0.045 0.51 (0.23–1.13) 0.096 0.34 (0.14–0.82) 0.016 0.30 (0.12–0.74) 0.009
Ter2 0.70 (0.36–1.35) 0.285 0.66 (0.33–1.33) 0.248 0.78 (0.38–1.61) 0.504 0.70 (0.34–1.45) 0.339
Ter3 Reference - Reference - Reference - Reference -
Model 1: unadjusted; Model 2: adjusted for age at start of immunosuppression, sex, time from biopsy to start of immunosup-
pressive therapy, and baseline estimated glomerular filtration rate (eGFR); Model 3: Model 2 + time-averaged proteinuria before 
the start of immunosuppressive therapy and time-averaged systolic blood pressure; Model 4: Model 3 + serum albumin, pres-
ence of endocapillary hypercellularity and use of renin-angiotensin system blocker at start of immunosuppressive therapy.
HR, hazard ratio; CI, confidence interval; Ter1, first tertile; Ter2, second tertile; Ter3, third tertile.
aDisease progression was defined as the occurrence of ≥ 30% decline in eGFR or end-stage renal disease.
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tor [16,32]. This finding can explain the higher risk of 
disease progression in the Ter2 group in our study, and 
underscores the importance of a sustained decrease in 
proteinuria in IgAN. 
Another important finding to note is that patients 
with the greatest proteinuria reduction in response to 
immunosuppression had greater preservation of their 
eGFR at the start of immunosuppression and a shorter 
time from biopsy to commencement of immunosup-
pression. These findings have several important clini-
cal implications. First, our results support the current 
guidelines suggesting that immunosuppression be 
considered in patients with preserved kidney function 
(eGFR ≥ 50 mL/min/1.73 m2) and be avoided in patients 
with advanced stages of CKD. Because fibrosis is consid-
ered an irreversible change and immunosuppression is 
not effective in patients with severe fibrosis, we exclud-
ed eight patients with eGFR < 30 mL/min/1.73 m2 and a 
T2 score from our analyses. Despite similar proportions 
of T1 scores and other pathologic lesions among tertile 
groups, we found that responsiveness to immunosup-
pression was greater in patients with a higher eGFR at 
baseline. Thus, treatment responses are likely to be bet-
ter in patients with preserved kidney function. Second, 
based on our findings, early commencement of immu-
nosuppression may be more effective in IgAN than late 
commencement. Few studies have examined the timing 
of initiation of immunosuppression. In general, IgAN 
is an indolent disease and rapid progression rarely oc-
curs. Thus, it is particularly difficult to determine when 
to commence immunosuppression in patients with an 
eGFR of 60 mL/min/1.73 m2 and proteinuria of 1.0 g/
day. Such patients would likely experience unfavorable 
outcomes if proteinuria reduction is not achieved given 
the preexisting evidence that risk of disease progression 
increases markedly in patients with proteinuria ≥ 1.0 g/
day [16,18]. It is possible that glomerular inflammation 
and tubular injury may still be ongoing despite maximal 
Figure 3. Adjusted survival curves of disease progression 
(disease progression was def ined as the occurrence of a 
30% or greater decline in estimated glomerular filtration 
rate [eGFR] or end-stage renal disease) for patients with 
immunoglobulin A nephropathy who underwent immuno-
suppressive therapy. Patients were categorized into tertiles 
according to the extent of time-averaged proteinuria reduc-
tion after immunosuppression. Adjustments were made for 
age at start of treatment, sex, time from biopsy to start of 
treatment, baseline eGFR, time-averaged proteinuria before 
the start of immunosuppressive therapy, time-averaged sys-
tolic blood pressure, serum albumin, presence of endocap-
illary hypercellularity and use of renin-angiotensin system 
blocker at start of immunosuppressive therapy. Ter1, f irst 
tertile; Ter2, second tertile; Ter3, third tertile.
Figure 4. Restricted cubic spline curve for disease progres-
sion (disease progression was defined as the occurrence of 
a 30% or greater decline in estimated glomerular filtration 
rate [eGFR] or end-stage renal disease) according to the ex-
tent of time-averaged proteinuria reduction. The shaded 
area represents the 95% confidence interval. Adjustments 
were made for age at start of treatment, sex, time from bi-
opsy to start of treatment, baseline eGFR, time-averaged 
proteinuria before the start of immunosuppressive therapy, 
time-averaged systolic blood pressure, serum albumin, 
presence of endocapillary hypercellularity and use of re-
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supportive care such as the use of RAAS blockers and 
a low protein diet. Future trials should address wheth-
er early initiation of immunosuppression can improve 
kidney outcomes.
There have been attempts to use the Oxford-MESTC 
score for risk stratification in IgAN. However, no con-
sensus has yet been reached regarding this issue. Only 
the T-score has been shown to consistently predict ad-
verse kidney outcomes, and studies to date have yield-
ed conflicting results on which pathologic components 
can convincingly predict disease progression [33]. As 
described above, we found no significant difference in 
Oxford-MESTC score among tertile groups accord-
ing to the extent of proteinuria reduction. Studies on 
the relationship between the Oxford score and respon-
siveness to immunosuppression are scarce. The initial 
Working Group study showed a significant interaction 
between endocapillary hypercellularity and corticoste-
roid use, but this requires further validation [13]. Find-
ing pathologic features that can correctly predict treat-
ment response is very important, because utilization of 
such lesions can aid in decision-making with regards 
to the timing of initiation of immunosuppression. Un-
fortunately, no randomized controlled trials have been 
conducted to address this issue. In this regard, we are 
awaiting the results from the ongoing Treatment of IgA 
nEphropathy according to Renal lesions (TIGER) study, 
which is a prospective, open-labelled, randomized con-
trolled study to evaluate the efficacy of early cortico-
steroid therapy combined with RAAS blockade (versus 
RAAS blockade alone) after 2 years of evolution in IgAN 
patients with severe histological lesions [34]. 
This study has several limitations. First, it was an 
observational study with a relatively small sample size. 
Thus, the influences of confounding factors could not 
be controlled for and causality between treatment and 
outcome could not be determined. Baseline character-
istics did not differ much among tertile groups, but it 
is possible that other unmeasured factors might have 
affected proteinuria reduction. Second, the immuno-
suppression protocol was not uniform and there was no 
pre-set regimen, dosage, or duration of immunosup-
pression although all patients were initially treated with 
corticosteroids based on similar protocols suggested by 
the current KDIGO guidelines [9]. In addition, further 
immunosuppression with other drugs was allowed at 
the physician’s discretion. Future studies should use a 
well-designed immunosuppression protocol to robustly 
determine the relationship between the use of immuno-
suppression and proteinuria reduction. Third, our da-
tabase did not include detailed information on adverse 
side effects of immunosuppression. We reviewed med-
ical records and found five events of severe infection 
and seven events of new diabetes mellitus during the 
follow-up period. The incidence rate of severe infection 
in our study was lower than that reported in previous 
randomized controlled studies [10,11], possibly because 
we routinely administered prophylactic antibiotics to all 
patients during immunosuppressive treatment period. 
Nevertheless, fatal adverse effects of immunosuppres-
sion should not outweigh the effect of immunosuppres-
sion on delaying disease progression. Finally, our study 
was not designed to compare treatment effects between 
immunosuppression and supportive care. However, 
proteinuria reduction can be achieved spontaneously or 
with intensive supportive care. Further studies are need-
ed to evaluate the relationship between proteinuria re-
duction and risk of long-term adverse kidney outcomes 
in IgAN patients. 
In conclusion, we showed that greater proteinuria re-
duction after immunosuppression was associated with 
a lower risk of disease progression in IgAN, suggesting 
that proteinuria reduction after immunosuppression 
may be a surrogate marker for responsiveness to im-
munosuppression and a useful predictor of long-term 
kidney outcomes.
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KEY MESSAGE
1. Greater proteinuria reduction after immuno-
suppressive therapy is associated with a lower 
risk of disease progression in immunoglobu-
lin A nephropathy.
2. Proteinuria reduction after immunosuppres-
sive therapy may be a surrogate marker for 
responsiveness to immunosuppression and 
predictor of long-term kidney outcomes. 
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Supplementary Table 1. Baseline characteristics of patients with biopsy-proven immunoglobulin A nephropathy who under-




Tertiles of proteinuria reduction after  
immunosuppressive therapy p value
Ter1 (n = 43) Ter2 (n = 42) Ter3 (n = 42)
Demographic data
Proteinuria, g/gCr 1.8 (1.2–3.3) 3.8 (2.0–5.1) 1.5 (1.2–1.9) 1.6 (0.8–2.3) < 0.001
Age at biopsy, yr 39.6 ± 11.3 38.3 ± 9.9 39.7 ± 10.9 41.0 ± 12.9 0.54
Female sex 79 (62.2) 34 (79.1) 22 (52.4) 23 (54.8) 0.019
BMI, kg/m2 23.4 (21.3–26.4) 23.3 (21.1–26.9) 24.0 (22.4–26.9) 23.1 (20.6–25.0) 0.16
SBP, mmHg 121.2 ± 14.6 123.9 ± 20.5 120.9 ± 11.3 118.9 ± 9.4 0.34
DBP, mmHg 76.4 ± 9.9 78.0 ± 11.0 77.3 ± 9.2 74.1 ± 9.2 0.19
Laboratory parameters
BUN, mg/dL 15.7 (13.0–18.5) 13.9 (12.4–17.3) 16.5 (13.0–19.8) 16.7 (14.9–19.1) 0.043
Creatinine, mg/dL 1.0 (0.8–1.3) 0.9 (0.6–1.2) 1.1 (0.8–1.4) 1.1 (0.9–1.3) 0.029
eGFR, mL/min/1.73 m2 79.3 (61.2–103.3) 85.2 (66.3–109.7) 73.3 (58.2–99.3) 76.0 (64.4–93.8) 0.18
Hemoglobin, g/dL 12.9 ± 1.8 12.9 ± 1.6 13.2 ± 1.9 12.6 ± 1.8 0.28
Calcium, mg/dL 8.9 (8.6–9.3) 8.8 (8.5–9.1) 9.1 (8.6–9.3) 9.0 (8.7–9.3) 0.052
Inorganic phosphorus, mg/dL 3.7 ± 0.6 3.7 ± 0.5 3.6 ± 0.6 3.8 ± 0.6 0.31
Uric acid, mg/dL 5.9 (4.7–6.9) 5.3 (4.4–6.7) 6.1 (5.1–7.1) 6.4 (5.0–7.0) 0.098
Total protein, g/dL 6.4 (6.1–6.9) 6.3 (5.7–6.8) 6.6 (6.2–7.0) 6.5 (6.1–7.0) 0.084
Albumin, g/dL 3.8 (3.5–4.1) 3.6 (3.2–4.0) 3.9 (3.7–4.2) 3.8 (3.6–4.2) 0.002
Total cholesterol, mg/dL 201.0 (174.0–235.0) 221.0 (201.0–270.0) 192.5 (178.0–214.0) 186.0 (164.0–223.0) < 0.001
HDL-C, mg/dL 48.5 (40.0–61.0) 51.5 (41.5–61.5) 41.0 (40.0–57.0) 53.0 (41.0–64.0) 0.38
LDL-C, mg/dL 121.0 (106.0–150.0) 126.0 (116.0–181.0) 110.5 (93.0–142.0) 125.0 (110.0–135.0) 0.11
Triglyceride, mg/dL 140.0 (93.0–219.0) 148.5 (108.0–220.0) 186.0 (115.0–244.0) 118.0 (76.0–148.0) 0.053
Na, mmol/L 140.7 ± 1.9 140.1 ± 2.1 141.0 ± 2.0 140.8 ± 1.6 0.088
K, mmol/L 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 0.57
Cl, mmol/L 104.3 ± 2.3 104.4 ± 2.3 104.1 ± 2.2 104.5 ± 2.2 0.77
tCO2, mmol/L 25.7 ± 2.3 25.6 ± 2.3 25.8 ± 2.3 25.7 ± 2.4 0.95
Comorbidities
HTN 104 (81.9) 35 (81.4) 33 (78.6) 36 (85.7) 0.69
DM 14 (11.0) 3 (7.0) 5 (11.9) 6 (14.3) 0.53
CVD 4 (3.1) 0 2 (4.8) 2 (4.8) 0.39
CHD 4 (3.1) 2 (4.7) 0 2 (4.8) 0.54
Medication history
ACE inhibitor 5 (3.9) 0 2 (4.8) 3 (7.1) 0.23
ARB 78 (61.4) 20 (46.5) 29 (69.0) 29 (69.0) 0.047
Spironolactone 6 (4.7) 3 (7.0) 1 (2.4) 2 (4.8) 0.87
Statin 30 (23.6) 11 (25.6) 7 (16.7) 12 (28.6) 0.41
Values are presented as median (interquartile range), mean±standard deviation, or number (%).
Ter1, first tertile; Ter2, second tertile; Ter3, third tertile; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cho-
lesterol; LDL-C, low-density lipoprotein cholesterol; HTN, hypertension; DM, diabetes mellitus; CVD, cerebrovascular dis-
ease; CHD, coronary heart disease; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker. 
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Supplementary Table 2. Cox proportional hazard model of disease progressiona according to reduction of proteinuria after 
immunosuppressive therapy in subgroups divided by baseline proteinuria
Variable
Model 1 Model 2 Model 3
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Patients whose Pre-IS TAP ≥ 3.0 g/gCr (n = 34)
Ter1 0.88 (0.25–3.08) 0.846 0.83 (0.16–4.14) 0.816 0.54 (0.09–3.05) 0.484
Ter2 0.51 (0.11–2.46) 0.403 0.51 (0.11–2.45) 0.398 1.32 (0.16–11.18) 0.796
Ter3 Reference Reference Reference
Patients whose Pre-IS TAP < 3.0 g/gCr (n = 93)
Ter1 0.40 (0.12–1.29) 0.125 0.32 (0.09–1.14) 0.079 0.31 (0.08–1.16) 0.082
Ter2 0.90 (0.43–1.87) 0.769 0.98 (0.47–2.08) 0.968 0.98 (0.47–2.05) 0.951
Ter3 Reference Reference Reference
Model 1: adjusted for age at start of immunosuppression, sex, time from biopsy to start of immunosuppressive therapy, and 
baseline estimated glomerular filtration rate (eGFR); Model 2: Model 2 + pre-IS TAP and time-averaged systolic blood pressure; 
Model 3: Model 3 + serum albumin, presence of endocapillary hypercellularity and use of renin-angiotensin system blocker at 
start of immunosuppressive therapy. 
HR, hazard ratio; CI, confidence interval; pre-IS TAP, time-averaged proteinuria before the start of immunosuppressive thera-
py; Ter1, first tertile; Ter2, second tertile; Ter3, third tertile.
aDisease progression was defined as the occurrence of ≥ 30% decline in eGFR or end-stage renal disease.
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Supplementary Figure 1. Differences in time-averaged proteinuria within 12 months before and after the start of immunosup-
pression. Patients were categorized into tertiles according to the extent of time-averaged proteinuria reduction after immuno-
suppression. Markers and capped spikes represent means and 95% confidence intervals. TAP, time-averaged proteinuria; Ter1, 
first tertile; Ter2, second tertile; Ter3, third tertile. aTime points were from the start of immunosuppression therapy.
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Supplementary Figure 2. Changes in time-averaged pro-
teinuria in immunoglobulin A nephropathy patients who 
underwent immunosuppressive therapy. Patients were 
categorized into tertiles according to the extent of time-av-
eraged proteinuria reduction after immunosuppression. 
Markers and capped spikes represents means and standard 
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